Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia. 2012

Naoyuki Miyashita, and Yasuhiro Kawai, and Hiroto Akaike, and Kazunobu Ouchi, and Toshikiyo Hayashi, and Takeyuki Kurihara, and Niro Okimoto, and
Department of Internal Medicine , Kawasaki Medical School, Okayama, Japan. nao@med.kawasaki-m.ac.jp

BACKGROUND Although the prevalence of macrolide-resistant Mycoplasma pneumoniae isolates in Japanese pediatric patients has increased rapidly, there have been no reports concerning macrolide-resistant M. pneumoniae infection in adolescents aged 16 to 19 years old. The purpose of this study was to clarify the prevalence and clinical characteristics of macrolide-resistant M. pneumoniae in adolescent patients with community-acquired pneumonia. METHODS A total of 99 cases with M. pneumoniae pneumonia confirmed by polymerase chain reaction (PCR) and culture were analyzed. Forty-five cases were pediatric patients less than 16 years old, 26 cases were 16 to 19-year-old adolescent patients and 28 cases were adult patients. Primers for domain V of 23S rRNA were used and DNA sequences of the PCR products were compared with the sequence of an M. pneumoniae reference strain. RESULTS Thirty of 45 pediatric patients (66%), 12 of 26 adolescent patients (46%) and seven of 28 adult patients (25%) with M. pneumoniae pneumonia were found to be infected with macrolide-resistant M. pneumoniae (MR patients). Although the prevalence of resistant strains was similar in pediatric patients between 2008 and 2011, an increase in the prevalence of resistant strains was observed in adolescent patients. Among 30 pediatric MR patients, 26 had an A-to-G transition at position 2063 (A2063G) and four had an A-to-G transition at position 2064 (A2064G). In 12 adolescent MR patients, 10 showed an A2063G transition and two showed an A2064G transition, and in seven adult MR patients, six showed an A2063G transition and one showed an A2064G transition. CONCLUSIONS The prevalence of macrolide-resistant M. pneumoniae is high among adolescent patients as well as pediatric patients less than 16-years old. To prevent outbreaks of M. pneumoniae infection, especially macrolide-resistant M. pneumoniae, in closed populations including among families, in schools and in university students, physicians should pay close attention to macrolide-resistant M. pneumoniae.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009177 Mycoplasma pneumoniae Short filamentous organism of the genus Mycoplasma, which binds firmly to the cells of the respiratory epithelium. It is one of the etiologic agents of non-viral primary atypical pneumonia in man. Eaton Agent
D011019 Pneumonia, Mycoplasma Interstitial pneumonia caused by extensive infection of the lungs (LUNG) and BRONCHI, particularly the lower lobes of the lungs, by MYCOPLASMA PNEUMONIAE in humans. In SHEEP, it is caused by MYCOPLASMA OVIPNEUMONIAE. In CATTLE, it may be caused by MYCOPLASMA DISPAR. Mycoplasma Pneumonia,Pneumonia, Primary Atypical,Mycoplasma dispar Infection,Mycoplasma ovipneumoniae Infection,Mycoplasma pneumoniae Infection,Atypical Pneumonia, Primary,Atypical Pneumonias, Primary,Mycoplasma Pneumonias,Mycoplasma dispar Infections,Mycoplasma ovipneumoniae Infections,Mycoplasma pneumoniae Infections,Pneumonias, Mycoplasma,Pneumonias, Primary Atypical,Primary Atypical Pneumonia,Primary Atypical Pneumonias
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Naoyuki Miyashita, and Yasuhiro Kawai, and Hiroto Akaike, and Kazunobu Ouchi, and Toshikiyo Hayashi, and Takeyuki Kurihara, and Niro Okimoto, and
November 2020, Indian journal of pediatrics,
Naoyuki Miyashita, and Yasuhiro Kawai, and Hiroto Akaike, and Kazunobu Ouchi, and Toshikiyo Hayashi, and Takeyuki Kurihara, and Niro Okimoto, and
July 2020, Emerging infectious diseases,
Naoyuki Miyashita, and Yasuhiro Kawai, and Hiroto Akaike, and Kazunobu Ouchi, and Toshikiyo Hayashi, and Takeyuki Kurihara, and Niro Okimoto, and
November 2009, Respirology (Carlton, Vic.),
Naoyuki Miyashita, and Yasuhiro Kawai, and Hiroto Akaike, and Kazunobu Ouchi, and Toshikiyo Hayashi, and Takeyuki Kurihara, and Niro Okimoto, and
January 2014, Internal medicine (Tokyo, Japan),
Naoyuki Miyashita, and Yasuhiro Kawai, and Hiroto Akaike, and Kazunobu Ouchi, and Toshikiyo Hayashi, and Takeyuki Kurihara, and Niro Okimoto, and
February 2020, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit,
Naoyuki Miyashita, and Yasuhiro Kawai, and Hiroto Akaike, and Kazunobu Ouchi, and Toshikiyo Hayashi, and Takeyuki Kurihara, and Niro Okimoto, and
January 2014, Swiss medical weekly,
Naoyuki Miyashita, and Yasuhiro Kawai, and Hiroto Akaike, and Kazunobu Ouchi, and Toshikiyo Hayashi, and Takeyuki Kurihara, and Niro Okimoto, and
January 2019, BioMed research international,
Naoyuki Miyashita, and Yasuhiro Kawai, and Hiroto Akaike, and Kazunobu Ouchi, and Toshikiyo Hayashi, and Takeyuki Kurihara, and Niro Okimoto, and
April 2010, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Naoyuki Miyashita, and Yasuhiro Kawai, and Hiroto Akaike, and Kazunobu Ouchi, and Toshikiyo Hayashi, and Takeyuki Kurihara, and Niro Okimoto, and
June 2011, The European respiratory journal,
Naoyuki Miyashita, and Yasuhiro Kawai, and Hiroto Akaike, and Kazunobu Ouchi, and Toshikiyo Hayashi, and Takeyuki Kurihara, and Niro Okimoto, and
February 2016, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
Copied contents to your clipboard!